Aardvark Therapeutics, Inc. (NASDAQ:AARD – Get Free Report) has been assigned a consensus recommendation of “Hold” from the nine research firms that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $11.06.
Several analysts have commented on AARD shares. UBS Group set a $4.00 target price on shares of Aardvark Therapeutics in a research report on Monday, October 19th. Weiss Ratings downgraded shares of Aardvark Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday. Wall Street Zen downgraded Aardvark Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, November 14th. HC Wainwright dropped their target price on shares of Aardvark Therapeutics from $4.00 to $2.00 and set a “hold” rating on the stock in a research report on Monday, October 26th. Finally, BTIG Research dropped coverage on shares of Aardvark Therapeutics in a research report on Monday, October 12th. They set a “neutral” rating for the company.
View Our Latest Stock Report on Aardvark Therapeutics
Aardvark Therapeutics Stock Performance
Shares of AARD opened at $0.91 on Thursday. The company has a market capitalization of $19.92 million, a PE ratio of -0.27 and a beta of 4.38. The company’s 50 day moving average price is $3.51 and its 200 day moving average price is $5.54. Aardvark Therapeutics has a 52 week low of $0.91 and a 52 week high of $16.60.
Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) last released its earnings results on Friday, November 13th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.19). On average, equities analysts forecast that Aardvark Therapeutics will post -3.17 earnings per share for the current fiscal year.
Insider Activity at Aardvark Therapeutics
In other news, insider Nelson Sun sold 62,000 shares of the firm’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $5.18, for a total transaction of $321,160.00. Following the completion of the transaction, the insider directly owned 35,475 shares of the company’s stock, valued at approximately $183,760.50. This trade represents a 63.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 17.80% of the company’s stock.
Institutional Investors Weigh In On Aardvark Therapeutics
A number of institutional investors have recently added to or reduced their stakes in AARD. BlackRock Inc. acquired a new stake in Aardvark Therapeutics in the 2nd quarter valued at $1,077,000. Marshall Wace LLP boosted its holdings in shares of Aardvark Therapeutics by 593.0% in the 3rd quarter. Marshall Wace LLP now owns 132,204 shares of the company’s stock worth $697,000 after acquiring an additional 113,128 shares in the last quarter. Renaissance Technologies LLC bought a new stake in Aardvark Therapeutics during the 1st quarter worth approximately $267,000. J. Goldman & Co LP acquired a new stake in Aardvark Therapeutics during the 2nd quarter valued at $233,000. Finally, Ieq Capital LLC acquired a new position in Aardvark Therapeutics in the second quarter worth $221,000.
Aardvark Therapeutics Company Profile
Aardvark Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California. It develops oral medicines for metabolic disorders, with a focus on conditions involving excessive hunger and disrupted energy balance. The company’s lead candidate, ARD-101, is an investigational oral therapy designed to activate bitter taste receptors in the gut and influence gut-brain signaling. Aardvark has studied the candidate for hyperphagia, or excessive hunger, associated with Prader-Willi syndrome and hypothalamic obesity.
Recommended Stories
- Five stocks we like better than Aardvark Therapeutics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Aardvark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aardvark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
